Monte Rosa Therapeutics (GLUE) Profit After Tax (2020 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly Profit After Tax came in at -$45.4 million in Q1 2026, down 196.82% year-on-year from $46.9 million in Q1 2025, and up 1.49% quarter-over-quarter from -$46.1 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Profit After Tax (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$45.4 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 196.82% year-over-year to -$45.4 million in Q1 2026; TTM through Mar 2026 was -$130.9 million, a 2643.86% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, up 47.36% from the prior year.
- Profit After Tax climbed to -$45.4 million in Q1 2026 per GLUE's latest filing, from -$46.1 million in the prior quarter.
- Across five years, Profit After Tax topped out at $46.9 million in Q1 2025 and bottomed at -$46.1 million in Q4 2025.
- The 5-year median for Profit After Tax is -$30.2 million (2022), against an average of -$23.6 million.
- Biggest YoY gain for Profit After Tax was 246.75% in 2025; the steepest drop was 471.76% in 2025.
- Year by year, Profit After Tax stood at -$30.2 million in 2022, then fell by 11.25% to -$33.6 million in 2023, then surged by 136.92% to $12.4 million in 2024, then tumbled by 471.76% to -$46.1 million in 2025, then increased by 1.49% to -$45.4 million in 2026.
- Per Business Quant, the three latest GLUE Profit After Tax figures stand at -$45.4 million (Q1 2026), -$46.1 million (Q4 2025), and -$27.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -45.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.42 Mn |
| Dec 31, 2025 | -46.11 Mn |
| Sep 30, 2025 | -27.08 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | 46.91 Mn |
| Dec 31, 2024 | 12.40 Mn |
| Sep 30, 2024 | -23.86 Mn |
| Jun 30, 2024 | -30.31 Mn |
| Mar 31, 2024 | -31.97 Mn |
| Dec 31, 2023 | -33.60 Mn |
| Sep 30, 2023 | -34.70 Mn |
| Jun 30, 2023 | -35.18 Mn |
| Mar 31, 2023 | -32.04 Mn |
| Dec 31, 2022 | -30.20 Mn |
| Sep 30, 2022 | -27.32 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -23.93 Mn |
| Dec 31, 2021 | -23.48 Mn |
| Sep 30, 2021 | -19.84 Mn |
| Jun 30, 2021 | -18.41 Mn |